Cardiac Magnetic Resonance Utilities in the Evaluation of Ischemic Heart Disease

Brief Summary

Official Title: “CARDIAC MAGNETIC RESONANCE UTILITIES IN THE EVALUATION OF ISCHEMIC HEART DISEASE: Topographical Correlation Between Ischemic Territory Injury and Coronary Angiography”

The purpose of this study is to evaluate CARDIAC MAGNETIC RESONANCE UTILITIES IN THE ISCHEMIC HEART DISEASE as topographical correlation between ischemic territory injury and coronary angiography.

  • Study Type: Observational
  • Study Design: Time Perspective: Prospective
  • Study Primary Completion Date: December 2014

Detailed Clinical Trial Description

Assessing the accuracy of Cardio-RM identifying ischemic territories and their correspondence to the presence of critical coronary lesions, comparing the presence, extent and regional inducible ischaemia in the Cardiac-MRI with the presence and characteristics of vascular lesions in coronary angiography.

In particular, the study aims to evaluate the correlation between topography and function of the ischemic area revealed by the resonance and coronary artery disease documented coronary angiography.

Interventions Used in this Clinical Trial

  • Other: Cardiac magnetic resonance – CINE MRI stress test.
    • Cardiac magnetic resonance – dipyridamole or dobutamine MRI stress test.

Arms, Groups and Cohorts in this Clinical Trial

  • suspected Myocardial Ischemia
    • Patient with diagnosis of suspected coronary artery disease (CAD) or recurrent ischemic symptoms assessed by under-effort angina symptoms and/or cardiac conventional stress test, and the presence of at least two risk factors.

Outcome Measures for this Clinical Trial

Primary Measures

  • Accuracy of Cardio-RM identifying ischemic territories
    • Time Frame: 1 month
      Safety Issue?: No

Secondary Measures

  • correlation between resonance and coronary artery disease documented coronary angiography.
    • Time Frame: 1 month
      Safety Issue?: No
  • topographic correlation between ischemic territory and coronary lesions
    • Time Frame: 1 month
      Safety Issue?: No

Criteria for Participation in this Clinical Trial

Inclusion Criteria

1. patients with suspected ischemic heart disease or recurrent Myocardial ischemic symptoms defined as:

  • presence of:
  • chest pain related to the effort lasting 5-20 minutes, and / or
  • positive stress test for inducible Myocardial ischemia
  • presence of at least one of the following risk factors: smoke family history of cardiovascular disease hypertension dyslipidemia diabetes mellitus NID / ID

2. no contraindications to perform coronary angiography

3. informed written consent to the processing of personal and sensible data, signed and dated by the patient.

Exclusion Criteria

  • Unstable angina;
  • Severe aortic stenosis
  • Hypertrophic cardiomyopathy
  • Pacemaker and \ or defibrillator
  • Coronary stent implantation in 90 days before Cardiac MRI
  • Intracranial metal clips
  • Severe hypertension (systolic blood pressure> 240 mmHg, and diastolic blood pressure above 120 mmHg)
  • Ventricular thrombosis and \ or atrial
  • Aortic aneurysm and \ or aortic dissection
  • Myocarditis, endocarditis, pericarditis
  • Critical stenosis of the left notes
  • State of severe anxiety or claustrophobia
  • Contraindications to the use of atropine (BAV advanced glaucoma, pyloric stenosis, prostatic hypertrophy)

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: N/A

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial: No

Clinical Trial Investigator Information

  • Lead Sponsor
    • Ettore Sansavini Health Science Foundation
  • Provider of Information About this Clinical Study
    • Sponsor


Clinical Trials content is provided directly by the US National Institutes of Health via and is not reviewed separately by Every page of information about a specific clinical trial contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is: